Healthcare Realty Trust Incorporated (NYSE: HR), initiation of coverage, Nov 13, 2026
Healthcare Realty’s clinics are filling up, but its cash grows slowly, so we see downside
Healthcare Realty owns 560 outpatient medical buildings, mostly beside hospitals, and doctors renew 88% of their suites. But refits and commissions take about 16% of property income, so cash per share grows only 3.0% a year, like cheaper landlords.
- Our rating
- Hold
- 12-month target
- $17.38
- Price, Nov 10, 2026
- $19.35
- Expected return, with dividend
- −5%
By Penmark Team
What Healthcare Realty is now
A landlord to hospitals and doctors whose buildings are filling up
Healthcare Realty owns or co-owns 560 outpatient medical buildings in 49 US markets. 73% sit on or next to hospital campuses, and no tenant brings in 10% of revenue.
Occupancy in its core buildings rose from 89.3% in early 2025 to 93.1% in 3Q26, and renewals in 3Q26 came at 8.6% higher cash rent.
Occupancy is the share of space leased in the 520 buildings owned throughout. Source: Q3 2026 Supplemental.
Cash leasing spread is new cash rent against expiring cash rent. Source: Q3 2026 Supplemental.
What you are really buying
At $19.35 you pay 14.1 times the cash it can pay out
Investors judge the shares on funds from operations, the usual REIT earnings measure, at 11.0x for 2027. But of $579.1m in 2026, $115.0m goes back into suite refits, commissions and upkeep, and $22.7m is rent not yet received in cash.
That leaves $441.4m, or $1.27 a share, of cash it can pay out. On $1.37 a share of 2027 cash the stock costs 14.1 times, against 12.5 for long-lease landlords.
Funds from operations is Normalised FFO; cash available to pay out is company FAD (funds available for distribution). Source: Q3 2026 Supplemental, Penmark Research estimates.
Where we disagree: the cash multiple
Paying what similar landlords cost cuts $2.82 a share off value
Tenants of net-lease landlords pay for roofs and interiors, so those landlords turn about 95% of earnings into cash. Healthcare Realty turns 76.2% to 78.1%, yet both grow cash per share 3.0% a year.
At the peer multiple of 12.52x on $1.37 of 2027 cash, our base value is $17.15 a share, against $19.35 today.
Cash per share is FAD, the REIT equivalent of AFFO. Peers are O, ADC, NNN, WPC, BNL and EPRT. Source: Q3 2026 releases, Penmark Research estimates.
Where we disagree: debt costs
Cheap bonds reset near 6%, lifting cash interest 35% by 2030
$1.75bn of notes at 2.4% to 3.75% mature from 2027 to 2030, and we refinance most at 6.00%. Cash interest climbs from $139.6m in 2026 to $188.1m in 2030.
The price implies a 4.07% 10-year Treasury yield against 4.98% today, or 7.22% yearly cash growth against our 3.0%.
Cash interest excludes the non-cash HTA merger debt adjustment. Source: Q3 2026 Supplemental, Penmark Research estimates.
Where we disagree: earnings
We expect more earnings than analysts, yet it adds only $0.62 a share
Campus leasing, signed leases not yet occupied and redevelopments lift our 2027 funds from operations to $1.75 a share, 3.8% above analysts’ $1.69.
That beat adds $0.62 a share to value. It is not enough: cash per share still grows only 3.0% a year from 2027 to 2030.
Funds from operations is Normalised FFO per share. Source: Zacks and Capital IQ consensus, Penmark Research estimates.
The odds
Only the good case clears today’s price
Our bad case, with two Fed rate rises and slower rent growth, is worth $14.13, 27.0% below the price. Our middle case is worth $17.15, 11.3% below.
Only the good case, with lower rates and fuller buildings, beats today at $19.73. Weighting the three and adding 12 months gives our $17.38 target.
- Good, 20%The 10-year yield falls 50bp to 4.48%, same-store growth reaches 5.5% in 2027 and occupancy passes 94%.
- Middle, 50%Yields stay at 4.98%, same-store growth of 4.5% fades to 3.25%, and 2027 cash of $1.37 a share is valued at 12.5 times.
- Bad, 30%Two Fed rises lift the 10-year yield to 5.48%, same-store growth slows to 3.0% and refits take 17.5% of property income.
Circle size shows how likely we think each case is. The target weights all three and adds 12 months of expected return. Source: Penmark Research.
What would change our mind
A 50bp rise in yields or higher refit costs is downside to this Hold
Our conviction is low: six robustness checks in Section 15 set Low conviction. Downside to Hold is a 50bp rise in the 10-year yield (−$1.01 a share), 17.5% TI/LC (−$0.40) or 3.0% FY27 same-store growth (−$0.30) toward our $14.65 bear target.
The tests come soon: the FOMC decision on 9 December, 2027 guidance in mid-February and the $500m note maturity in July 2027.
The 10-year yield is 4.98%; a 50bp move is about −$1.01 or +$1.15 a share.
We expect $1.75 of funds from operations a share and $114.6m of refits; analysts expect $1.69.
More than $100m of sales under letter of intent, at prices near a 5.5% yield.
The 3.75% notes move onto a term loan at about 4.8% until May 2029.
Inside the full report
What each page covers after the summary on pages 1 and 2. Each opens the full report at that page.
See all 23 pages
- 3We sit +3.8% above FY27E FFO consensus ($1.75 vs $1.69), yet 78% FAD conversion puts HR at 14.1x cash flow
- 4HR trades +18.0% above peer FY26E P/AFFO (15.2x vs 12.9x) and +0.2 SD above its mean ahead of rate and refi tests
- 5Six exhibits trace why +3.8% FFO upside still leaves HR 15.4% above probability-weighted cash value ($16.76, −13.4%)
- 6Debates 1–3 bridge $19.35 to $16.76 weighted value (−$2.82 multiple, +$0.62 FFO, −$0.39 rates); Debate 4 explains NAV
- 7Doctors renew 88% of their clinic suites, yet 20 cents of every FFO dollar goes back into TI, commissions and upkeep
- 8Same-store outpatient leases generate 94% of HR’s $684.8m FY26E cash NOI, but only 64% ($441.4m) reaches FAD
- 9Campus adjacency (73% of MOBs) and 11%–14% staggered lease roll lift FY27E cash NOI +4.6% to $716.2m
- 1062.8m older Americans (18.4% of U.S. population) support outpatient demand, while public MOBs trade 87bp wide of core JVs
- 11HR beats Healthpeak on outpatient retention (88.0% vs 81.7%), yet ranks last against net-lease peers on cash retention
- 12New leadership delivered three FY26 raises and ~$255m of YTD buybacks, but cash bonuses omit FAD/sh
- 13Four drivers govern HR: sector rates explain 47.9% of weekly moves, while the market under-prices TI/LC cash drag by $2.82/sh
- 14Analysts asked 48 questions on debt/rates and just 15 on TI/LC, matching where the stock misprices cash
- 19Dispositions shrank GAAP revenue 12.1% (FY23–25), while non-cash add-backs leave FAD 23.4% below NFFO in 9M26
- 20Cash NOI compounds at 3.9% (FY26E–30E), but straight-line roll-off and debt resets cap FAD/sh growth at 3.0%
- 21We sit +3.8% above FY27E NFFO consensus ($1.75 vs $1.69), yet ±1pp operating shifts leave value at $15.95–$18.41
- 22Peer-anchored P/AFFO (12.52x FY27E FAD) yields $17.15 base value and a $17.38 target (−10.2%); NAV ($21.68) cross-checks
- 23$17.38 target implies −5.0% total return (Hold, inside ±10.0%); six robustness tests set Low conviction
- 24Six dated milestones over 14 months test our $17.38 target; FOMC rates and Feb 2027 guidance test our Hold rating
- 25Macro rates (−$1.01/+$1.15) and private MOB caps (−$1.23/+$1.33) dominate our $17.15 base value and Hold band
- 26Dedicated REIT funds and indexers dominate the register; short interest is 17.0m shares (2.6 days) and 0 of 12 Street analysts rate HR Sell
- 27Annual NOI, FFO, FAD, cash flow and balance sheet (FY24A–FY30E): FAD reaches $500.9m in FY29E before FY30E bond resets
- 28Quarterly KPIs, debt refinancing ladder (30 Sep 2026–FY30E) and per-share valuation ratios at $19.35 and $17.38 target
- 29GAAP-to-FAD reconciliation, REIT glossary, ratio definitions, peer selection and model methodology
Penmark Research. This summary draws on our initiation report on Healthcare Realty Trust Incorporated, published Nov 13, 2026. It is not investment advice. Analyst certification, rating definitions and important disclosures are in the full report.